Dental management of the classic hemophiliac with inhibitors

Spencer W. Redding, Kim E. Stiegler

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Approximately 15 percent of patients with hemophilia A will develop inhibitors (antibodies) to Factor VIII after replacement infusion. Since Factor VIII replacement therapy is the mainstay of treatment in the hemophiliac, destruction of infused Factor VIII by inhibitors presents significant problems in the treatment of these patients. Different methods of treatment are discussed, including infusion of high doses of Factor VIII and infusion of prothrombin-complex concentrate. Two inhibitor patients who presented for dental treatment are examined. One patient had very low inhibitor titers, and the other had very high inhibitor titers. These patients show that dental treatment must be individualized according to severity of the disease process.

Original languageEnglish (US)
Pages (from-to)145-148
Number of pages4
JournalOral Surgery, Oral Medicine, Oral Pathology
Volume56
Issue number2
DOIs
StatePublished - 1983

Fingerprint

Tooth
Factor VIII
Therapeutics
Hemophilia A
Antibodies

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Dentistry(all)

Cite this

Dental management of the classic hemophiliac with inhibitors. / Redding, Spencer W.; Stiegler, Kim E.

In: Oral Surgery, Oral Medicine, Oral Pathology, Vol. 56, No. 2, 1983, p. 145-148.

Research output: Contribution to journalArticle

Redding, Spencer W. ; Stiegler, Kim E. / Dental management of the classic hemophiliac with inhibitors. In: Oral Surgery, Oral Medicine, Oral Pathology. 1983 ; Vol. 56, No. 2. pp. 145-148.
@article{b3287ab2a8414bf9a747ea32cd8b5589,
title = "Dental management of the classic hemophiliac with inhibitors",
abstract = "Approximately 15 percent of patients with hemophilia A will develop inhibitors (antibodies) to Factor VIII after replacement infusion. Since Factor VIII replacement therapy is the mainstay of treatment in the hemophiliac, destruction of infused Factor VIII by inhibitors presents significant problems in the treatment of these patients. Different methods of treatment are discussed, including infusion of high doses of Factor VIII and infusion of prothrombin-complex concentrate. Two inhibitor patients who presented for dental treatment are examined. One patient had very low inhibitor titers, and the other had very high inhibitor titers. These patients show that dental treatment must be individualized according to severity of the disease process.",
author = "Redding, {Spencer W.} and Stiegler, {Kim E.}",
year = "1983",
doi = "10.1016/0030-4220(83)90279-7",
language = "English (US)",
volume = "56",
pages = "145--148",
journal = "Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology",
issn = "2212-4403",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Dental management of the classic hemophiliac with inhibitors

AU - Redding, Spencer W.

AU - Stiegler, Kim E.

PY - 1983

Y1 - 1983

N2 - Approximately 15 percent of patients with hemophilia A will develop inhibitors (antibodies) to Factor VIII after replacement infusion. Since Factor VIII replacement therapy is the mainstay of treatment in the hemophiliac, destruction of infused Factor VIII by inhibitors presents significant problems in the treatment of these patients. Different methods of treatment are discussed, including infusion of high doses of Factor VIII and infusion of prothrombin-complex concentrate. Two inhibitor patients who presented for dental treatment are examined. One patient had very low inhibitor titers, and the other had very high inhibitor titers. These patients show that dental treatment must be individualized according to severity of the disease process.

AB - Approximately 15 percent of patients with hemophilia A will develop inhibitors (antibodies) to Factor VIII after replacement infusion. Since Factor VIII replacement therapy is the mainstay of treatment in the hemophiliac, destruction of infused Factor VIII by inhibitors presents significant problems in the treatment of these patients. Different methods of treatment are discussed, including infusion of high doses of Factor VIII and infusion of prothrombin-complex concentrate. Two inhibitor patients who presented for dental treatment are examined. One patient had very low inhibitor titers, and the other had very high inhibitor titers. These patients show that dental treatment must be individualized according to severity of the disease process.

UR - http://www.scopus.com/inward/record.url?scp=0020956392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020956392&partnerID=8YFLogxK

U2 - 10.1016/0030-4220(83)90279-7

DO - 10.1016/0030-4220(83)90279-7

M3 - Article

C2 - 6225980

AN - SCOPUS:0020956392

VL - 56

SP - 145

EP - 148

JO - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

JF - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

SN - 2212-4403

IS - 2

ER -